InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,568.40
(
-0.25%
)
Dow Jones
38,884.26
(
0.00%
)
Brent Oil
81.94
(
-1.12%
)
Bitcoin
62,318.21
(
-0.03%
)
Post# of 251750
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119591
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 223535

Tuesday, 05/07/2019 4:24:28 PM

Tuesday, May 07, 2019 4:24:28 PM

Post# of 251750
ENTA FY2Q19 results:

https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-Second-Quarter-Ended-March-31-2019/default.aspx

FY2Q19 royalty revenue was $39.6M, down from $69.9M in FY1Q19 (Oct-Dec 2018). ENTA’s royalty rate from ABBV resets to the lowest tier at the start of each calendar year, so ENTA’s fiscal 2Q (Jan-Mar) will always have the lowest royalty tier for a given fiscal year.

(The royalty tiers applicable to the 50% Glecaprevir component of Mavyret are shown in #msg-142808661.)

ENTA’s cash balance at 3/31/19 was $387M.

FY2Q19 GAAP EPS was $0.20, due to a tax benefit.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up